Product Name: Axl (699-706) pY702+pY703
Product Number: PE-04AHN75
Size: | 200 µg | | Price: | 74.00 |
| 1 mg | | $US | 148.00 |
| 5 mg | | | 325.00 |
Peptide Name: Axl (699-706) pY702+pY703
Product Use: Services as a blocking peptide for use with the Axl-pY702+pY703 rabbit polyclonal antibody (Cat. No.: AB-PK533) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y702 and Y703 phosphorylation stimulate phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: NGD-pY-pY-RQG
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Scientific Background: Axl (UFO) is a protein-tyrosine kinase of the TK group and Axl family. It is a receptor kinase for its ligand growth arrest-specific gene-6 (GAS6), which is a growth factor that drives cell proliferation. GAS6 is a vitamin K-dependent protein structurally similar to Protein S (PROS1), which activates MERTK and TYRO3 but not Axl. The extracellular domain contains six N-linked glycosylation sites,and this generates two other post-translationally modified forms of 120 and 140 kDa represent partial and complete glycosylation, respectively. Phosphorylation of Y821 induces interactions with Grb2, PIK3R1, PIK3R2, and PLCG1.Some of Axl signalling pathways involve PI3K/Akt, Ras and ERK MAP kinases. It regulates cell survival and proliferation, preventing apoptosis, migration, cell adhesion, cell aggregation and homophillic binding. Mutation of Axl at E63R, E66R, and T84R reduces its affinity for GAS6. Axl is expressed most tissue and cell types, with highest in endothelial cells, heart and skeletal muscle, liver, kidney, testis, platelets, myelomonocytic cells, hippocampus, and cerebellum. Axl is overexpressed in numerous human cancers, including thyroid carcinomas, myeloproliferative disorders, prostatic carcinoma cells, and breast cancer. Its up-regulation in expression contributes to metastasis and invasion, and in most cases negatively correlates with prognosis.